NEOGENOMICS ($NEO) posted quarterly earnings results for Q4 2025 on Tuesday, February 17th. The company reported earnings of $0.06 per share, beating estimates of $0.04 by $0.02. The company also reported revenue of $190,170,000, beating estimates of $189,929,338 by $240,662.
You can see Quiver Quantitative's $NEO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NEOGENOMICS Insider Trading Activity
NEOGENOMICS insiders have traded $NEO stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $NEO stock by insiders over the last 6 months:
- ALICIA C OLIVO (EVP, GC & Business Development) has made 0 purchases and 2 sales selling 25,834 shares for an estimated $300,172.
- WARREN STONE (Pres & Chief Operating Officer) sold 22,128 shares for an estimated $276,681
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NEOGENOMICS Hedge Fund Activity
We have seen 114 institutional investors add shares of NEOGENOMICS stock to their portfolio, and 148 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST LIGHT ASSET MANAGEMENT, LLC added 3,080,837 shares (+45.0%) to their portfolio in Q3 2025, for an estimated $23,784,061
- MILLENNIUM MANAGEMENT LLC added 2,657,818 shares (+80.1%) to their portfolio in Q3 2025, for an estimated $20,518,354
- MACQUARIE GROUP LTD removed 2,542,339 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $29,897,906
- D. E. SHAW & CO., INC. added 2,362,229 shares (+252.6%) to their portfolio in Q3 2025, for an estimated $18,236,407
- DEERFIELD MANAGEMENT COMPANY, L.P. added 2,299,331 shares (+107.0%) to their portfolio in Q3 2025, for an estimated $17,750,835
- CITADEL ADVISORS LLC added 2,126,943 shares (+364.3%) to their portfolio in Q3 2025, for an estimated $16,419,999
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,955,279 shares (-60.0%) from their portfolio in Q3 2025, for an estimated $15,094,753
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NEOGENOMICS Government Contracts
We have seen $4,795,076 of award payments to $NEO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- STX SPECIALIZED REFERENCE LABORATORY TESTING: $2,787,350
- FISH TESTING BPA FOR VISN1 VA: $500,000
- OFF-SITE ANATOMIC PATHOLOGY LAB SERVICES VACCHCS ORDERING PERIOD 5 (6) MONTH TASK ORDER: $325,000
- TASK ORDER FOR SERVICES ORDERING PERIOD 5 OFF-SITE ANATOMIC PATHOLOGY LAB SERVICES VACCHCS: $325,000
- IMMUNOHISTOCHEMISTRY (IHC) TESTING: $211,500
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
NEOGENOMICS Analyst Ratings
Wall Street analysts have issued reports on $NEO in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 01/12/2026
- TD Cowen issued a "Buy" rating on 09/12/2025
- Stephens & Co. issued a "Overweight" rating on 09/02/2025
To track analyst ratings and price targets for NEOGENOMICS, check out Quiver Quantitative's $NEO forecast page.
NEOGENOMICS Price Targets
Multiple analysts have issued price targets for $NEO recently. We have seen 3 analysts offer price targets for $NEO in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Mike Matson from Needham set a target price of $14.0 on 01/12/2026
- Dan Brennan from TD Cowen set a target price of $12.0 on 09/12/2025
- Mason Carrico from Stephens & Co. set a target price of $11.0 on 09/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
